Company / Depreciation & Amortization
ResMed Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$198.5M
FY2025
5-year range
$156.8M / $198.5M
FY2021-FY2025
Trend
+12.2%
vs FY2024
Sector context
#41 of 135
Health Care
What the data says
At $198M, ResMed's depreciation & amortization ranks #95 of 135 in the Health Care sector. Depreciation & Amortization has increased for 9 consecutive years, from $87M in FY2016 to $198M in FY2025.
Based on SEC 10-K filings.
$198M in FY2025 with a 5-year CAGR of +5.1%.
Increased from $165M to $198M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +7.5%
- 5-Year CAGR
- +5.1%
- 10-Year CAGR
- -
Sector benchmark
#95 of 135 in Health CareTop 70% of 135This company $198.5M Sector average $334.5M
▼
-40.7% below sector average
Key checks
Key Insights
- ResMed's depreciation & amortization has grown for 9 consecutive years.
- 5-year CAGR of +5.1%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 12.2% year-over-year.
- Ranks #41 out of 135 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- Strong profit margin: 27.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $198.5M | +12.2% |
| FY2024 | $176.9M | +7.1% |
| FY2023 | $165.2M | +3.5% |
| FY2022 | $159.6M | +1.8% |
| FY2021 | $156.8M | +1.2% |
| FY2020 | $154.8M | +2.7% |
| FY2019 | $150.8M | +25.7% |
| FY2018 | $120.0M | +7.0% |
| FY2017 | $112.2M | +29.1% |
| FY2016 | $86.8M | +18.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026